[CAS NO. 28860-95-9] Carbidopa

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [28860-95-9]

Catalog

HY-B0311

Brand

MCE

CAS

28860-95-9

DESCRIPTION [28860-95-9]

Overview

MDL	MFCD00069231
Molecular Weight	226.23
Molecular Formula	C10H14N2O4
SMILES	OC1=C(O)C=CC(CC(NN)(C(O)=O)C)=C1

For research use only. We do not sell to patients.

Summary

Carbidopa ((S)-(-)-Carbidopa), a peripheral decarboxylase inhibitor, can be used for the research of Parkinson's disease. Carbidopa is a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa inhibits pancreatic cancer cell and tumor growth ^[1] ^[2] .

In Vitro

Carbidopa ((S)-(-)-Carbidopa) exhibits activities similar to that described for other AhR ligands in BχPC3 and Capan-2 cells, namely the induction of CYP1A1 and CYP1A2, which are inhibited by AhR antagonists such as CH223191 ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Carbidopa also induces nuclear uptake of the AhR, and in vivo studies show that carbidopa at a dose of 1 mg/mouse significantly inhibits tumor growth in athymic nude mice bearing BχPC3 cells as xenografts ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01229332	NeuroDerm Ltd.	Parkinson´s Disease	January 2011	Phase 1\|Phase 2
NCT04325503	University of Michigan	Parkinsonian Signs in Older Persons	October 18, 2019	Phase 1\|Phase 2
NCT01437293	New York State Psychiatric Institute\|National Institute on Drug Abuse (NIDA)\|Columbia University	Cocaine Abuse	August 2010	Phase 1
NCT04006210	NeuroDerm Ltd.	Parkinson´s Disease	August 27, 2019	Phase 3
NCT00914602	XenoPort, Inc.	Parkinson´s Disease	May 2009	Phase 1\|Phase 2
NCT04723147	Emory University\|National Institute of Mental Health (NIMH)	Depression\|Anhedonia	January 29, 2021	Phase 4
NCT03115827	Vanderbilt University Medical Center\|H. Lundbeck A+S\|American Academy of Neurology	Parkinson Disease	April 18, 2017	Phase 4
NCT01212484	NYU Langone Health	Familial Dysautonomia	December 2009	Phase 3
NCT00685919	Vanderbilt University\|Vanderbilt University Medical Center	Postural Tachycardia Syndrome\|Orthostatic Intolerance	May 2008	Phase 2\|Phase 3
NCT01399905	Oregon Health and Science University	Parkinson´s Disease	March 2009	Phase 2
NCT01883505	NeuroDerm Ltd.	Parkinson´s Disease	December 2013	Phase 2
NCT00845000	Merck Sharp & Dohme LLC\|Oregon Health and Science University	Parkinson Disease	April 21, 2009	Phase 1
NCT01296464	Orion Corporation, Orion Pharma	Parkinson´s Disease	February 2011	Phase 2
NCT04952194	Second Affiliated Hospital, School of Medicine, Zhejiang University	Parkinson Disease	January 1, 2022	Phase 4
NCT03266965	University of Miami\|United States Department of Defense	Multiple Sclerosis	March 23, 2018	Phase 1
NCT00562198	Orion Corporation, Orion Pharma	Parkinson´s Disease	January 2008	Phase 2
NCT01568073	Bial - Portela C S.A.	Parkinson´s Disease	March 2011	Phase 3
NCT00693862	Orion Corporation, Orion Pharma	Pharmacokinetics	December 2006	Phase 1
NCT00223717	Vanderbilt University\|Vanderbilt University Medical Center	Hypertension	January 2001	Phase 1
NCT02553265	NYU Langone Health	Dysautonomia, Familial\|Baroreflex Failure Syndrome	September 2015	Phase 2
NCT02346630	Ross D. Zafonte, MD\|Spaulding Rehabilitation Hospital	Stroke	March 2015	Phase 4
NCT00357994	AbbVie (prior sponsor, Abbott)\|Quintiles, Inc.\|AbbVie	Advanced Parkinson´s Disease	January 2009	Phase 3
NCT04513340	Hong Kong WD Pharmaceutical Co., Limited	Parkinson Disease	August 13, 2020	Phase 1
NCT04246437	Daniel Claassen\|Vanderbilt University Medical Center	Autonomic Failure\|Pure Autonomic Failure\|Parkinson Disease\|Multiple System Atrophy\|Dementia With Lewy Bodies	February 4, 2020	Phase 1
NCT05250141	Laboratorios Andromaco S.A.	Bioequivalence	February 14, 2022	Phase 1
NCT04000919	Jessica M D´Amico\|University of Louisville	Spinal Cord Injuries	June 19, 2019	Phase 2\|Phase 3
NCT00505843	Merck Sharp & Dohme LLC	Parkinson´s Disease	May 2007	Phase 1
NCT04742348	University of Washington	Alcohol Drinking	April 2021	Phase 4
NCT00547911	National Institute of Neurological Disorders and Stroke (NINDS)\|National Institutes of Health Clinical Center (CC)	Parkinson Disease\|Multiple System Atrophy\|Autonomic Nervous System Diseases	October 2007	Phase 1\|Phase 2
NCT01468012	New York State Psychiatric Institute	Cocaine Dependence	July 2014	Phase 2\|Phase 3
NCT00660387	AbbVie (prior sponsor, Abbott)\|Quintiles, Inc.\|AbbVie	Advanced Parkinson´s Disease	December 2009	Phase 3
NCT04520178	University of Alberta\|Wings for Life	Spinal Cord Injuries	July 1, 2020	Phase 2\|Phase 3
NCT02116465	Desitin Arzneimittel GmbH	Fasted State	March 2014	Phase 1
NCT01725802	NeuroDerm Ltd.	Parkinson´s Disease	December 2012	Phase 1\|Phase 2
NCT02096601	NeuroDerm Ltd.\|Michael J. Fox Foundation for Parkinson´s Research	Parkinson´s Disease	August 2014	Phase 1\|Phase 2
NCT02633007	Acorda Therapeutics	Asthma	December 2015	Phase 1
NCT00218075	The University of Texas Health Science Center, Houston\|National Institute on Drug Abuse (NIDA)\|University of Texas	Cocaine Abuse\|Cocaine-Related Disorders	March 2000	Phase 2
NCT02633839	Acorda Therapeutics	Smoking	December 2015	Phase 1
NCT01766258	Orion Corporation, Orion Pharma	Parkinson´s Disease	May 2011	Phase 2
NCT03055936	Orion Corporation, Orion Pharma	Healthy Volunteers	February 21, 2017	Phase 1
NCT01323374	Chelsea Therapeutics	Fibromyalgia	January 2009	Phase 2
NCT01171313	XenoPort, Inc.	Parkinson´s Disease	July 2010	Phase 2
NCT03496870	Neurocrine Biosciences	Parkinson Disease	February 8, 2018	Phase 1
NCT01227655	Bial - Portela C S.A.	Parkinson´s Disease	March 2011	Phase 3
NCT00174239	Pfizer	Parkinson Disease	July 2004	Phase 4
NCT00134966	Novartis	Parkinson´s Disease	August 2005	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 10 mg/mL ( 44.20 mM ; Need ultrasonic)

H ₂ O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.4203 mL	22.1014 mL	44.2028 mL
5 mM	0.8841 mL	4.4203 mL	8.8406 mL
10 mM	0.4420 mL	2.2101 mL	4.4203 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 50% PEG300 >> 50% saline

Solubility: 10 mg/mL (44.20 mM); Suspended solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 1 mg/mL (4.42 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 1 mg/mL (4.42 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 1 mg/mL (4.42 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

Benzenepropanoic acid, α-hydrazinyl-3,4-dihydroxy-α-methyl-, (αS)-

Hydrocinnamic acid, α-hydrazino-3,4-dihydroxy-α-methyl-, L-

Benzenepropanoic acid, α-hydrazino-3,4-dihydroxy-α-methyl-, (S)-

Benzenepropanoic acid, α-hydrazino-3,4-dihydroxy-α-methyl-, (αS)-

(αS)-α-Hydrazinyl-3,4-dihydroxy-α-methylbenzenepropanoic acid

L-α-Hydrazino-α-methyl-β-(3,4-dihydroxyphenyl)propionic acid

MK 486

L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid

L-α-Methyl-α-hydrazino-β-(3,4-dihydroxyphenyl)propionic acid

L-α-Methyl-β-(3,4-dihydroxyphenyl)-α-hydrazinopropionic acid

L-α-Methyldopahydrazine

Carbidopa

(-)-L-α-Hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid monohydrate

L-α-(3,4-Dihydroxybenzyl)-α-hydrazinopropionic acid

1-α-(3,4-Dihydroxybenzyl)-α-hydrazinopropionic acid

(-)-L-α-Hydrazino-3,4-dihydroxy-α-methylhydrocinamic acid

α-Hydrazino-α-methyl-β-(3,4-dihydroxyphenyl)propionic acid

α-Methyldopahydrazine

Hydrazino-α-methyldopa

L-α-Hydrazino-α-methyl-3,4-dihydroxyphenylpropionic acid

L-α-Methyl-α-hydrazino-3,4-dihydroxyphenylpropionic acid

N-Aminomethyldopa

L-α-Hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid

Lodosyn

HMD

Lodosin

(S)-Carbidopa

L-Carbidopa

(2S)-2-(Aminoazaniumyl)-3-(3,4-dihydroxyphenyl)-2-methylpropanoate

(2S)-3-(3,4-Dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid

Cabidopa